PDF(Pubmed)
Abstract：
Cutaneous squamous cell carcinoma (cSCC) is the second most common type of skin cancer arising from squamous cells of the epidermis. Most cases of cSCC have a good prognosis if detected and treated early; however, certain cases can be aggressive. The primary risk factor for cSCC is prolonged ultraviolet radiation from sun exposure, leading to DNA mutations. Other risk factors have also been observed, including adverse reactions to medications, particularly immunosuppressants. A query of the Food and Drug Administration Adverse Events Reporting System (FAERS) was done, and all reported events of cSCC as adverse events to medication were recorded along with demographic data of patients affected. A total of 4,792 cases of cSCC as an adverse event to medication were reported between 1997 and 2023. Lenalidomide, a chemotherapeutic drug, had the most cases of cSCC as an adverse event. Nine of the top 10 drugs associated with cSCC had immunosuppressive characteristics. While males had higher odds of cSCC associated with corticosteroids and calcineurin inhibitors, females had higher odds of cSCC related to monoclonal antibodies. Geriatric patients accounted for the majority of cSCC cases at 59.7%. Drawing on data from the FAERS database, there\'s been a consistent increase in cSCC cases as a side-effect to certain medications, with most having immunosuppressive characteristics. Since there is a lack of up-to-date literature overviewing the most implicated medications for cSCC, we aimed to illustrate this better, as well as patient demographics, to better guide clinicians when prescribing these medications.
摘要：
皮肤鳞状细胞癌(cSCC)是由表皮鳞状细胞引起的第二最常见类型的皮肤癌。如果早期发现和治疗，大多数cSCC病例预后良好；然而，某些案件可能具有侵略性。cSCC的主要危险因素是长期暴露于阳光下的紫外线辐射，导致DNA突变.还观察到其他危险因素，包括药物不良反应，尤其是免疫抑制剂。对食品和药物管理局不良事件报告系统（FAERS）进行了查询，记录所有报告的cSCC事件作为药物不良事件以及受影响患者的人口统计学数据.在1997年至2023年之间，共报告了4,792例cSCC作为药物不良事件。来那度胺,一种化疗药物，作为不良事件的cSCC病例最多。与cSCC相关的前10种药物中有9种具有免疫抑制特征。虽然男性与皮质类固醇和钙调磷酸酶抑制剂相关的cSCC的几率较高，女性与单克隆抗体相关的cSCC几率较高。老年患者占大多数cSCC病例，占59.7%。根据FAERS数据库的数据，作为某些药物的副作用，cSCC病例持续增加，大多数具有免疫抑制特征。由于缺乏最新的文献来概述cSCC最牵连的药物，我们旨在更好地说明这一点，以及患者的人口统计学，更好地指导临床医生处方这些药物。
